玻璃体内氟轻松醋酸酯可能减缓糖尿病视网膜神经退行性变
本研究为回顾性分析,纳入USER研究中130例糖尿病黄斑水肿(DME)患者,在玻璃体内氟轻松醋酸酯(FAc)植入前后每3个月进行光学相干断层扫描神经视网膜分析。结果显示,在距中心凹超过1.5 mm的黄斑区域,FAc治疗后糖尿病视网膜神经退行性变(DRN)速率较治疗前显著降低(4.0 μm/年 vs 1.1 μm/年,P=0.001)。作者认为FAc可能减缓持续性DME患者的内层视网膜变薄速率,但需进一步前瞻性研究。
要点
- 在距中心凹超过1.5 mm的黄斑区域,FAc治疗后神经视网膜丢失速率由4.0 μm/年降至1.1 μm/年(P=0.001)。
- 距中心凹1.5 mm以内区域未报告显著变化。
- 作者认为FAc可能减缓持续性DME患者的内层视网膜变薄速率。
核心结论
- 这项回顾性研究提示,FAc可能减缓持续性DME患者的内层视网膜变薄速率。
- 作者指出,尚需进一步前瞻性研究来确定FAc对DME患者DRN速率的影响。
研究设计与样本
- 回顾性分析,纳入USER研究中的130例患者,在FAc给药前(平均903天,范围35至4005天)和给药后(平均408天,范围7至756天)每3个月进行光学相干断层扫描神经视网膜分析。
- DRN速率定义为内神经视网膜厚度随时间的变化,采用逻辑回归计算;分别计算距中心凹1.5 mm以内区域(区域1)和距中心凹1.5 mm至3.0 mm区域(区域2)的DRN速率。
主要发现
- 在距中心凹超过1.5 mm的黄斑区域,FAc治疗后DRN速率较治疗前显著降低:治疗前神经视网膜丢失速率为4.0 μm/年,治疗后为1.1 μm/年(P=0.001)。
- 距中心凹1.5 mm以内区域的DRN速率变化未在原文中报告。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性研究。
- 作者指出,尚需进一步前瞻性研究来确定FAc对DME患者DRN速率的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is no prevention or treatment for diabetic retinal neurodegeneration (DRN), which is a complication of diabetes that can occur independently of diabetic retinopathy (DR). We hypothesized that an intravitreal fluocinolone acetonide (FAc) implant may affect the rate of DRN when used in patients with diabetic macular edema (DME). METHODS: In this retrospective analysis, optical coherence tomography with neuroretinal analysis was obtained at 3-month intervals from 130 patients in the USER study both before (mean duration 903 days, range 35-4005 days) and after administration of FAc (mean 408 days, range 7 to 756 days). The rate of DRN was defined as the change over time on inner neuroretinal thickness using logistic regression. A DRN rate was calculated independently for two areas: region 1 located within 1.5 mm of the fovea, and region 2 from 1.5 mm to 3.0 mm from the fovea. RESULTS: In regions of the macula more than 1.5 mm from the central fovea, there was a statistically significant decrease in the rate of DRN in the post-FAc period. The pre-FAc neuroretinal loss in this area occurred at 4.0 μm/y, compared with a post-FAc loss rate of 1.1 μm/y (P = 0.001). CONCLUSIONS: This retrospective study suggests that FAc may decelerate the rate of inner retinal thinning in patients with persistent DME. Further prospective studies are necessary to determine the effects of FAc on the rate of DRN in patients with DME.
引用
- Lynch SK, Lee K, Chen Z, et al. Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration. Invest Ophthalmol Vis Sci. 2019. PMID: 31100106. doi:10.1167/iovs.18-24643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。